NCT01829503View on ClinicalTrials.gov

Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

November 30, 2017

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

decitabine and cytarabine

OTHER

Supportive Care

blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics

Trial Locations (1)

15232

University of PIttsburgh Cancer Institute, Pittsburgh

All Listed Sponsors
lead

Annie Im, M.D.

OTHER

NCT01829503 - Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter